Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...
Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
16h
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Sanofi Healthcare India Pvt. Limited has announced receipt of marketing authorization for Rezurock (Belumosudil Tablets) in ...
Sanofi Healthcare India has received marketing authorization for Rezurock, a drug for chronic graft versus host disease (cGVHD). Approved by USFDA and CDSCO, Rezurock offers a new treatment for ...
The latest health news covers topics such as the Trump administration's legal positions on transgender care, CDC research ...
Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...
GlobalData on MSN4d
Sanofi increases ownership stake partaking in pharma buyback trendJust days after taking back some of the stake held by L’Oréal, Sanofi has agreed to repurchase its own shares worth €2bn ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback